Mydecine recently reported a positive Pre-IND meeting with the FDA for the MYCO-001 smoking cessation study According to the Center for Disease Control (“CDC”), tobacco is the leading cause of preventable deaths in the U.S. Following the FDA meeting, the company now intends to perform a Phase 2b study and then a Phase 3 study … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Reports Positive Pre-IND Meeting with FDA, Changes to Its Clinical Trial Approach; Plans Breakthrough Therapy Designation Request for MYCO-001”
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. The company recently made two announcements that show a more immediate response to providing mental health solutions, further strengthening its leadership role in the psychedelic drugs market. First, Mydecine announced that Health … Continue reading “NetworkNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Strengthening Leadership Role in Psychedelics Space”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) understands the potential of the psychedelic industry in regard to health care. While in its early stages, the industry is estimated to grow tremendously, and Delic seeks to capitalize on the sector’s potential to not only benefit millions of people dealing with mental health issues, but also create value … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeking to Tap Potential of Emerging Psychedelics in Health Care Space”
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recognizes the opportunity within the mental health treatment space and acknowledges the underlying issues affecting people living with these conditions, especially in the United States. Here, over 51.5 million people have experienced a mental health condition, with figures rising because of the pandemic. “As … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing for Adoption of and Wider Access to Psychedelic-Based Treatments”
NetworkNewsWire Editorial Coverage: Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change its activity in response to stimuli often produces stress-induced neuroplasticity, which plays a critical role in almost all mental disorders. The problem is conventional drugs have done little … Continue reading “Psychedelic Therapies Offer Hope for Mental Health”
Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needs Delic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness … Continue reading “Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Tackles Pandemic-era Mental Health Crises with Product R&D and Educational Efforts for the Application of Psychedelics Technology”
Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005 This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005”
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is working to make psychedelic-based treatments more accessible and affordable by leveraging its growing chain of clinics in the United States. In 2021, Delic completed the acquisitions of Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers (“KWC”). These acquisitions brought the number of operational … Continue reading “NetworkNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Ketamine Clinics Improving Accessibility and Reach, Helping Greatest Number of Patients”
Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics”
The global psychedelics market is estimated to hit $10.75 billion in 2027, with the alternative antidepressant drug market being valued at $15.98 billion in 2023 Already, 65% of individuals dealing with PTSD, depression, and anxiety in the United States believe that psychedelic medicine should be made available 83% of Americans living with these conditions are … Continue reading “Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Seeks to Capitalize on the Growing Market for Psychedelics in Healthcare”
